U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx Promotional Labeling - Accompanied by Full Prescribing Information
Promotional labeling for a prescription product that makes claims about it must be accompanied by the full Prescribing Information; digital pieces satisfy this with a clearly labeled, working link.
What is FDA Rx Promotional Labeling - Accompanied by Full Prescribing Information?
Promotional labeling for a prescription product that makes claims about it must be accompanied by the full Prescribing Information; digital pieces satisfy this with a clearly labeled, working link. Apply to brochures, detail aids, emails, branded websites, apps and other promotional labeling for a prescription drug.
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
email, print, digital, display, website, mobile_app, direct_mail, video
When does this rule take effect?
2026-10-07
What does this rule require?
Promotional labeling for a prescription product that makes claims about it must be accompanied by the full Prescribing Information; digital pieces satisfy this with a clearly labeled, working link.
How can marketing teams comply?
Apply to brochures, detail aids, emails, branded websites, apps and other promotional labeling for a prescription drug.
What is FDA Rx Promotional Labeling - Accompanied by Full Prescribing Information?
Promotional labeling for a prescription product that makes claims about it must be accompanied by the full Prescribing Information; digital pieces satisfy this with a clearly labeled, working link.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
email, print, digital, display, website, mobile_app, direct_mail, video
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
Request a free compliance scan of your homepage and book a time with Warrant.